CRISPR screens with trastuzumab emtansine in HER2-positive breast cancer cell lines reveal new insights into drug resistance
Our CRISPR screening approach with T-DM1 in HER2-positive breast cancer cell lines identified genes not previously implicated in T-DM1 sensitivity or resistance, including TSC1 and TSC2. These genes may inform new strategies to enhance T-DM1 therapy in the clinic.
Authors
- Francis W. Hunter (ORCID: https://orcid.org/0000-0002-9970-8679)
- Kyla N. Siemens
- Barbara Lipert
- Marcella Flinterman
- Tet Woo Lee (ORCID: https://orcid.org/0000-0002-2744-1784)
- Gitte Aarøe Dam (ORCID: https://orcid.org/0000-0003-3526-0171)
- Stephen M. F. Jamieson (ORCID: https://orcid.org/0000-0002-5485-9211)
- Aziza Khan (ORCID: https://orcid.org/0000-0001-9496-3104)
- Rebecca Airey
- Qian Yong
- Man Lu
Institutions
- Johnson & Johnson (United States) (US)
- University of Auckland (NZ)
- Cancer Society of New Zealand (NZ)
- Maurice Wilkins Centre (NZ)
Publication Details
- Journal
- Breast Cancer Research
- Published
- 2025-03-31
- DOI
- https://doi.org/10.1186/s13058-025-02000-1
- Citations
- 6
- Primary Topic
- Monoclonal and Polyclonal Antibodies Research
- Type
- article
- Field-Weighted Citation Impact
- 8.16
Funders
- Maurice and Phyllis Paykel Trust
- Cancer Research Trust New Zealand
- University of Auckland
- Daiichi-Sankyo
- Genentech
- Health Research Council of New Zealand